- Home
- LQDA
LQDA
Liquidia Corporation
as 05-20-2024 12:32pm EST
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer.
| Founded: | 2004 | Country: | United States |
| Employees: | N/A | City: | MORRISVILLE |
| Market Cap: | 969.3M | IPO Year: | 2018 |
| Target Price: | $21.60 | AVG Volume (30 days): | 815.3K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.56 | EPS Growth: | N/A |
| 52 Week Low/High: | $5.71 - $16.99 | Next Earning Date: | 05-13-2024 |
| Revenue: | $15,967,000 | Revenue Growth: | -5.72% |
| Revenue Growth (this year): | 241.17% | Revenue Growth (next year): | 191.65% |
Share on Social Networks:
Stock Insider Trading Activity of Liquidia Corporation (LQDA)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Kaseta Michael | LQDA | CFO and COO | Apr 12 '24 | Sell | $14.58 | 3,136 | $45,722.88 | 315,045 | SEC Form 4 |
| Moomaw Scott | LQDA | Chief Commercial Officer | Apr 12 '24 | Sell | $14.58 | 1,585 | $23,109.30 | 151,881 | SEC Form 4 |
| Saggar Rajeev | LQDA | Chief Medical Officer | Apr 12 '24 | Sell | $14.58 | 1,525 | $22,234.50 | 213,321 | SEC Form 4 |
| Schundler Russell | LQDA | General Counsel | Apr 12 '24 | Sell | $14.58 | 2,060 | $30,034.80 | 486,027 | SEC Form 4 |
| Adair Jason | LQDA | Chief Business Officer | Apr 11 '24 | Sell | $14.58 | 1,189 | $17,335.62 | 111,537 | SEC Form 4 |
| Kaseta Michael | LQDA | CFO and COO | Mar 19 '24 | Sell | $15.82 | 11,315 | $179,003.30 | 318,181 | SEC Form 4 |
| Kaseta Michael | LQDA | CFO and COO | Mar 19 '24 | Sell | $15.82 | 851 | $13,462.82 | 329,496 | SEC Form 4 |
| Saggar Rajeev | LQDA | Chief Medical Officer | Mar 18 '24 | Sell | $15.82 | 5,876 | $92,958.32 | 214,846 | SEC Form 4 |
| Saggar Rajeev | LQDA | Chief Medical Officer | Mar 18 '24 | Sell | $15.82 | 1,654 | $26,166.28 | 220,722 | SEC Form 4 |
| Moomaw Scott | LQDA | Chief Commercial Officer | Mar 18 '24 | Sell | $15.82 | 6,108 | $96,628.56 | 153,466 | SEC Form 4 |
| JEFFS ROGER | LQDA | Chief Executive Officer | Mar 18 '24 | Sell | $15.82 | 28,583 | $452,183.06 | 835,345 | SEC Form 4 |
| Schundler Russell | LQDA | General Counsel | Mar 15 '24 | Sell | $15.82 | 7,938 | $125,579.16 | 488,087 | SEC Form 4 |
| Schundler Russell | LQDA | General Counsel | Mar 15 '24 | Sell | $15.82 | 715 | $11,311.30 | 496,025 | SEC Form 4 |
| Adair Jason | LQDA | Chief Business Officer | Mar 15 '24 | Sell | $15.82 | 4,581 | $72,471.42 | 108,716 | SEC Form 4 |
| Adair Jason | LQDA | Chief Business Officer | Mar 15 '24 | Sell | $15.50 | 76 | $1,178.00 | 108,640 | SEC Form 4 |
| Adair Jason | LQDA | Chief Business Officer | Feb 29 '24 | Sell | $14.17 | 455 | $6,447.35 | 97,412 | SEC Form 4 |
| Adair Jason | LQDA | Chief Business Officer | Dec 18 '23 | Sell | $7.70 | 77 | $592.90 | 54,932 | SEC Form 4 |
| Saggar Rajeev | LQDA | Chief Medical Officer | Dec 15 '23 | Sell | $7.42 | 14,887 | $110,461.54 | 164,099 | SEC Form 4 |
| Caligan Partners LP | LQDA | Director10% Owner | Dec 14 '23 | Buy | $7.16 | 1,117,318 | $7,999,996.88 | 11,280,945 | SEC Form 4 |
| JEFFS ROGER | LQDA | Chief Executive Officer | Dec 14 '23 | Buy | $7.16 | 139,665 | $1,000,001.40 | 640,805 | SEC Form 4 |
| Lippe Robert A | LQDA | Chief Operations Officer | Nov 30 '23 | Sell | $7.28 | 497 | $3,618.16 | 193,788 | SEC Form 4 |
| Adair Jason | LQDA | Chief Business Officer | Nov 30 '23 | Sell | $7.28 | 452 | $3,290.56 | 54,478 | SEC Form 4 |
| Moomaw Scott | LQDA | Chief Commercial Officer | Nov 30 '23 | Sell | $7.28 | 542 | $3,945.76 | 106,737 | SEC Form 4 |
Latest Liquidia Corporation News
LQDA Breaking Stock News: Dive into LQDA Ticker-Specific Updates for Smart Investing
GuruFocus.com
5 days ago
Liquidia Corp (LQDA) Q1 2024 Earnings Call Transcript Highlights: A Detailed Review of ...
Thomson Reuters StreetEvents
5 days ago
Q1 2024 Liquidia Corp Earnings Call
Simply Wall St.
6 days ago
Liquidia (NASDAQ:LQDA) shareholders have earned a 64% CAGR over the last three years
Zacks
6 days ago
Down -11.26% in 4 Weeks, Here's Why You Should You Buy the Dip in Liquidia Technologies (LQDA)
GlobeNewswire
7 days ago
Liquidia Corporation Reports First Quarter 2024 Financial Results and Provides Corporate Update
GlobeNewswire
10 days ago
Liquidia Announces Poster Presentation at the American Thoracic Society (ATS) 2024 International Conference on Its Open-Label Safety Study of L606 (Liposomal Treprostinil) in Patients with PAH and PH-ILD
GlobeNewswire
13 days ago
Liquidia Corporation to Present at BofA Securities Health Care Conference 2024
GlobeNewswire
13 days ago